THE Covid-19 vaccine from Pfizer has now got 95 per cent efficacy in preventing coronavirus.
The vaccine is said to have met the safety criteria needed for emergency authorisation, according to the firms.
Pfizer and BioNTech say they plan to submit the COVID-19 vaccine to the US regulator for emergency use approval within days after ‘no serious safety concerns’ were reported.
The pharmaceutical giant and its partner BioNTech published interim results last week showing the jab could prevent more than 90% of people developing Covid-19.
That data was based on the first 94 volunteers to develop Covid-19, but further figures released today are based on the first 170 cases of the virus in the clinical trial.
The vaccine has been tested on 43,500 people in six countries and no safety concerns have been raised.
Another jab, from US firm Moderna, was shown this week in early data to be almost 95% effective.
The Pfizer vaccine has been shown to produce both an antibody and T-cell response in the body to fight coronavirus.
Pfizer and BioNTech expect to be able to produce up to 50m vaccine doses globally in 2020 and up to 1.3bn in 2021.
Pfizer’s chief executive, Albert Bourla, said on Tuesday that the firm was preparing to file for emergency use authorisation within days from the US Food and Drug Administration.Tags: